Allergy Therapeutics plc has announced the results of its Open Offer and Subscription, as well as the total voting rights and director dealing. The company has conditionally raised approximately £40.75 million through the Equity Financing, which will be used to repay amounts owed under the Loan Facility Agreement. The Open Offer received final valid applications from Qualifying Shareholders for a total of 240,550,224 Open Offer Shares, representing approximately 34.91% of the maximum number of Open Offer Shares available. ZQ Capital has agreed to underwrite the Open Offer and will subscribe for 448,552,308 Open Offer Shares not taken up by Qualifying Shareholders. In addition, Subscription Shares will be issued to ZQ Capital and Southern Fox. The total number of new Ordinary Shares to be issued and admitted to trading on AIM is 4,074,612,532. Following Admission, the Company will have 4,753,717,153 Ordinary Shares in issue.